gopubmed logo
 
find other proteinsAll proteins
GoPubMed Proteins lists recent and important papers and reviews for proteins. Page last changed on 23 May 2015.

Monoamine oxidase A

Monoamine Oxidase, MAO
enzyme involved in the oxidative deamination of biogenic and xenobiotic amines [RGD, Feb 2006] (from NCBI)
Top mentioned proteins: MAO-B, CAN, HAD, ACID, V1a
Papers on Monoamine Oxidase
Inhibition and oxygen activation in copper amine oxidases.
New
Impact
Dooley et al., Bozeman, United States. In Acc Chem Res, 19 Jun 2015
Inhibition of these enzymes by antifungal or antiprotozoal agents, as well as classic monoamine oxidase (MAO) inhibitors, may contribute to the adverse side effects associated with drug treatment.
Titanium(iv) catalysts with ancillary imino-spiroketonato ligands: synthesis, structure and olefin polymerization.
New
Coates et al., Ithaca, United States. In Dalton Trans, 18 Jun 2015
Upon activation with methylaluminoxane (MAO), these complexes catalyze the polymerization of ethylene and propylene.
New insights in the discovery of novel h-MAO-B inhibitors: structural characterization of a series of N-phenyl-4-oxo-4H-chromene-3-carboxamide derivatives.
New
Borges et al., Maia, Portugal. In Acta Crystallogr E Crystallogr Commun, 01 Jun 2015
Six N-substituted-phenyl 4-oxo-4H-chromene-3-carboxamides, namely N-(2-nitro-phen-yl)-4-oxo-4H-chromene-3-carboxamide, C16H10N2O5 (2b), N-(3-meth-oxy-phen-yl)-4-oxo-4H-chromene-3-carboxamide, C17H13NO4, (3a), N-(3-bromo-phen-yl)-4-oxo-4H-chromene-3-carboxamide, C16H10BrNO3, (3b), N-(4-methoxy-phen-yl)-4-oxo-4H-chromene-3-carboxamide, C17H13NO4, (4a), N-(4-methyl-phen-yl)-4-oxo-4H-chromene-3-carboxamide, C17H13NO3, (4d), and N-(4-hy-droxy-phen-yl)-4-oxo-4H-chromene-3-carboxamide, C16H11NO4, (4e), have been structurally characterized.
Imaging genetics studies on monoaminergic genes in major depressive disorder.
Review
New
Ham et al., Seoul, South Korea. In Prog Neuropsychopharmacol Biol Psychiatry, 27 Apr 2015
This paper attempts to provide a comprehensive review of available imaging genetics studies, including reports on genetic variants that have most frequently been linked to MDD, such as the monoaminergic genes (serotonin transporter gene, monoamine oxidase A gene, tryptophan hydroxylase-2 gene, serotonin receptor 1A gene and catechol-O-methyl transferase gene), with regard to key structures involved in emotion processing, such as the hippocampus, amygdala, anterior cingulate cortex and orbitofrontal cortex.
Monoamine oxidases are novel sources of cardiovascular oxidative stress in experimental diabetes.
New
Muntean et al., Timişoara / Temesvár, Romania. In Can J Physiol Pharmacol, 12 Apr 2015
Recently, monoamine oxidases (MAOs) at the outer mitochondrial membrane, with 2 isoforms, MAO-A and MAO-B, have emerged as novel sources of constant hydrogen peroxide (H2O2) production in the cardiovascular system via the oxidative deamination of biogenic amines and neurotransmitters.
Medicinal properties of Peganum harmala L. in traditional Iranian medicine and modern phytotherapy: a review.
Review
New
Gholamreza et al., In J Tradit Chin Med, Feb 2015
Because of increasing the expression of CYP1A2, 2C19, and 3A4 and inhibition of monoamine oxidase, the pharmacokinetic parameters of drugs which are mainly metabolized by these enzymes may be affected by P. harmala.
Profile of tedizolid phosphate and its potential in the treatment of acute bacterial skin and skin structure infections.
Review
New
Michaels et al., Dallas, United States. In Infect Drug Resist, Dec 2014
In vitro, animal, and clinical studies have failed to demonstrate that tedizolid inhibits monoamine oxidase to a clinically relevant extent.
Immunomodulatory Effects Mediated by Serotonin.
Review
New
Pavón et al., Mexico. In J Immunol Res, Dec 2014
Three classes of genes regulating 5-HT function are constitutively expressed or induced in these cells: (a) membrane proteins that regulate the response to 5-HT, such as SERT, 5HTR-GPCR, and the 5HT3-ion channels; (b) downstream signaling transduction proteins; and (c) enzymes controlling 5-HT metabolism, such as IDO and MAO, which can generate biologically active catabolites, including melatonin, kynurenines, and kynurenamines.
Catecholamine-Based Treatment in AD Patients: Expectations and Delusions.
New
Pierantozzi et al., Roma, Italy. In Front Aging Neurosci, Dec 2014
In reviewing the available literature, we consider the effects of levodopa, monoamine oxidase inhibitors, and noradrenaline (NE) modulators, showing disparate results.
Adjuvant therapies for HIV-associated neurocognitive disorders.
Review
New
Douglas et al., Philadelphia, United States. In Ann Clin Transl Neurol, Nov 2014
Multiple adjuvant therapies with various mechanisms of action have been studied (N-methyl D-aspartate [NMDA]-receptor antagonists, MAO-B inhibitors, tetracycline-class antibiotics, and others), but none have shown a clear positive effect in HAND.
Long-term effectiveness of dopamine agonists and monoamine oxidase B inhibitors compared with levodopa as initial treatment for Parkinson's disease (PD MED): a large, open-label, pragmatic randomised trial.
New
Impact
Clarke et al., In Lancet, Oct 2014
BACKGROUND: Whether initial treatment for Parkinson's disease should consist of levodopa, dopamine agonists, or monoamine oxidase type B inhibitors (MAOBI) is uncertain.
GABA from reactive astrocytes impairs memory in mouse models of Alzheimer's disease.
New
Impact
Lee et al., Taejŏn, South Korea. In Nat Med, Aug 2014
Here, we show that reactive astrocytes aberrantly and abundantly produce the inhibitory gliotransmitter GABA by monoamine oxidase-B (Maob) and abnormally release GABA through the bestrophin 1 channel.
Rasagiline and rapid symptomatic motor effect in Parkinson's disease: review of literature.
New
Zambito Marsala et al., Vicenza, Italy. In Neurol Ther, Jun 2014
Rasagiline is a monoamine oxidase type-B inhibitor used as monotherapy or in addition to levodopa in the treatment of Parkinson's disease.
Pharmacological treatment of Parkinson disease: a review.
Review
New
Impact
Lang et al., Hamilton, Canada. In Jama, May 2014
RESULTS: Although levodopa is the most effective medication available for treating the motor symptoms of Parkinson disease, in certain instances (eg, mild symptoms, tremor as the only or most prominent symptom, aged <60 years) other medications (eg, monoamine oxidase type B inhibitors [MAOBIs], amantadine, anticholinergics, β-blockers, or dopamine agonists) may be initiated first to avoid levodopa-related motor complications.
Genetic mediators of neurocognitive outcomes in survivors of childhood acute lymphoblastic leukemia.
Impact
Pui et al., Memphis, United States. In J Clin Oncol, 2013
Polymorphisms in monoamine oxidase (T1460CA) were associated with increased attention variability (P = .03).
Apolipoprotein E influences melatonin biosynthesis by regulating NAT and MAOA expression in C6 cells.
GeneRIF
Zhou et al., Hefei, China. In J Pineal Res, 2012
A higher level of melatonin was demonstrated in cultured ApoE4-C6 cells than in ApoE3-C6 cells. NAT was up-regulated in ApoE4-C6 cells compared with ApoE3-C6 cells, and MAOA and MAOB expression decreased in ApoE4-C6 cells.
²H kinetic isotope effects and pH dependence of catalysis as mechanistic probes of rat monoamine oxidase A: comparisons with the human enzyme.
GeneRIF
Edmondson et al., Atlanta, United States. In Biochemistry, 2011
Rat MAO A exhibits functional properties similar but not identical with those of the human enzyme, providing additional support for C-H bond cleavage via a polar nucleophilic mechanism
Topological probes of monoamine oxidases A and B in rat liver mitochondria: inhibition by TEMPO-substituted pargyline analogues and inactivation by proteolysis.
GeneRIF
Edmondson et al., Atlanta, United States. In Biochemistry, 2011
investigation of topological orientation of MAO-A (and MAO-B) in liver mitochondrial membranes
High-level expression and purification of rat monoamine oxidase A (MAO A) in Pichia pastoris: comparison with human MAO A.
GeneRIF
Edmondson et al., Atlanta, United States. In Protein Expr Purif, 2010
Although approximately 90% identical in sequence to human MAO A, rat MAO A is a more efficient catalyst for amine neurotransmitter oxidation.
Gonadectomy and hormone replacement exert region- and enzyme isoform-specific effects on monoamine oxidase and catechol-O-methyltransferase activity in prefrontal cortex and neostriatum of adult male rats.
GeneRIF
Kritzer et al., Stony Brook, United States. In Neuroscience, 2010
significant effects of hormone replacement and gonadectomy on catechol-O-methyltransferase and monoamine oxidase isoforms in both striatum and cortex
share on facebooktweetadd +1mail to friends